On August 10, the Justice Department announced a resolution exceeding $46 million with Veloxis Pharmaceuticals. One part of the case concerned payments to specialty pharmacies under agreements describing data collection and medication adherence services.
The contractual description sounded like an exchange of payment for work. The company’s settlement admissions described payments that continued without regard to whether that work was delivered.
That disconnect makes the case a useful illustration of a longstanding principle. A service contract does not resolve the Anti-Kickback Statute question. The purpose and operation of the payment still matter.
The Manufacturer Paid the Pharmacies
The civil settlement agreement, Recital E(3), identifies Enhanced Services Agreements covering data and/or adherence services to or for Veloxis. The manufacturer paid the pharmacies, including on a per-patient, per-month basis.
Veloxis admitted that the payments induced pharmacies to begin or continue purchasing Envarsus, its kidney transplant immunosuppression drug, instead of competitor drugs, including a cheaper generic. It admitted that the service descriptions disguised that purpose.
The same passage describes the operational facts. Payments continued regardless of whether pharmacies supplied data, the specified fields, or the required format. Even when data arrived, typically no one at Veloxis reviewed or used it. For adherence services, Veloxis did not know or confirm whether pharmacies performed services justifying payment.
The Missing Connection Was Between Payment and Performance
The account describes more than a missing approval or an incomplete file. Payment was disconnected from the work the agreements purported to purchase. Data that arrived typically went unused. Adherence work was unconfirmed.
Those details give substance to the admitted explanation that the service descriptions were pretextual. They allow the reader to follow the difference between what the contracts described and how the arrangements operated.
A company genuinely purchasing data would ordinarily need to know what data it requires, whether it received that data, and how the data serves its business purpose. A company purchasing adherence support would need a way to establish that the promised work occurred. These are practical observations about evaluating a service arrangement, rather than a separate legal test announced in this settlement.
Failure to verify work does not, standing alone, establish a kickback. Conversely, proof that some work occurred does not automatically establish that the payment was lawful. Courts have long held that a payment can violate the statute if even one purpose is to induce.
The Statute Reaches Purchases as Well as Referrals
The Anti-Kickback Statute prohibits knowingly and willfully paying remuneration to induce specified referrals or purchases involving items or services payable by federal healthcare programs, subject to the statutory exceptions and the regulatory safe harbors. It also provides that claims including items or services resulting from a violation constitute false or fraudulent claims for False Claims Act purposes.
The pharmacy arrangement illustrates the purchasing side of that prohibition. A manufacturer does not need to describe its payment as a referral fee for the inducement question to arise. Describing compensation as a service fee cannot answer what the money was intended to accomplish.
Nor does this resolution establish a new prohibition on data services, adherence support, or a particular payment unit. Their legitimacy depends on the arrangement and applicable legal protections. The lesson is to examine the transaction rather than rely on its title.
